Inhibrx concludes Phase I dose escalation of solid tumour therapy
The company received $60m from Oxford Finance under a Loan and Security Agreement.
Vishnu Priyan
Latest articles
All Articles
Ascentage Phase I cancer therapy trial receives FDA IND clearance
Dose-limiting toxicity, maximum tolerated dose and recommended Phase II dose of oral APG-5918 will be analysed in the trial.
Soligenix gets FDA clearance for Phase II psoriasis trial
The company plans to commence subject enrolment in the trial in the fourth quarter of this year.
Ascletis doses first participant in Phase II HIV-1 treatment trial
The trial will analyse the safety and efficacy of ASC22 along with ART versus placebo in HIV-1 patients.
Swing selects Curavit as virtual site for fibromyalgia DTx trial
Curavit’s decentralised clinical trial capabilities make it ideal for prescription and non-prescription DTx studies.
EnGeneIC’s Covid-19 vaccine offers protection against variants in trials
Increased neutralising antibody levels against all variants, including Omicron BA2, and memory response were observed in subjects.
Ceruvia’s Phase II obsessive-compulsive disorder trial receives FDA clearance
Analysing the decline in OCD symptoms for up to 12 weeks following a single dose of SYNP-101 is the…
Kiora gets approval to begin Phase Ib retinitis pigmentosa trial
The open-label, first-in-human, single ascending dose trial will analyse KIO-301 in individuals with retinitis pigmentosa.
Kezar reports positive Phase II data of zetomipzomib for lupus nephritis
In the trial, 64.7% of the trial subjects attained an ORR, which is the primary efficacy endpoint of the…